dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | De Mattos-Arruda, Leticia |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Blanco-Heredia, Juan |
dc.contributor.author | Tiezzi, Daniel G. |
dc.contributor.author | Gonçalves Ribeiro, Samuel |
dc.contributor.author | Ortega Cebrian, Vanesa |
dc.contributor.author | Cusco Pons, Pol |
dc.contributor.author | Fasani, Roberta |
dc.contributor.author | Nuciforo, Paolo Giovanni |
dc.contributor.author | Rubio Rodríguez, Isabel Teresa |
dc.contributor.author | Villacampa Javierre, Guillermo |
dc.contributor.author | Dienstmann, Rodrigo |
dc.date.accessioned | 2022-01-11T12:01:23Z |
dc.date.available | 2022-01-11T12:01:23Z |
dc.date.issued | 2021-06-07 |
dc.identifier.citation | De Mattos-Arruda L, Cortes J, Blanco-Heredia J, Tiezzi DG, Villacampa G, Gonçalves-Ribeiro S, et al. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. NPJ Breast Cancer. 2021 Jun 7;7:73. |
dc.identifier.issn | 2374-4677 |
dc.identifier.uri | https://hdl.handle.net/11351/6759 |
dc.description | Càncer de mama; Genòmica del càncer; Biomarcadors tumorals |
dc.description.sponsorship | This work was supported by Cancer Research UK. L.D.M.A. was partly funded by Spanish Association against cancer. |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | NPJ Breast Cancer;7 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Càncer - Aspectes genètics |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /therapy |
dc.subject.mesh | Neoadjuvant Therapy |
dc.subject.mesh | Mutation |
dc.title | The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41523-021-00282-0 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /terapia |
dc.subject.decs | tratamiento neoadyuvante |
dc.subject.decs | mutación |
dc.relation.publishversion | https://doi.org/10.1038/s41523-021-00282-0 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [De Mattos-Arruda L] IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK. [Cortes J] Oncology Department International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. Breast Cancer Research program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. [Blanco-Heredia J] IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. [Tiezzi DG] Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK. Breast Disease Division, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil. [Villacampa G, Gonçalves-Ribeiro S, Cusco P, Fasani R, Dienstmann R, Nuciforo P, Rubio IT] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ortega V] Breast Cancer Research program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34099718 |
dc.identifier.wos | 000658754600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |